I'm in the Department of Anesthesiology, Pharmacology, and Therapeutics and the Therapeutics Initiative @drug-evidence.bsky.social
I'll be doing all the causal inference & translational methodology research you love, plus helping the BC government answer pressing questions about medical treatments!
I'll be doing all the causal inference & translational methodology research you love, plus helping the BC government answer pressing questions about medical treatments!
November 2, 2026 at 9:42 PM
I'm in the Department of Anesthesiology, Pharmacology, and Therapeutics and the Therapeutics Initiative @drug-evidence.bsky.social
I'll be doing all the causal inference & translational methodology research you love, plus helping the BC government answer pressing questions about medical treatments!
I'll be doing all the causal inference & translational methodology research you love, plus helping the BC government answer pressing questions about medical treatments!
Philosophy of Natural Therapeutics 2
nmsnt.substack.com/p/philosophy...
nmsnt.substack.com/p/philosophy...
Philosophy of Natural Therapeutics 2
Lecture Given @ NMSNT Sometime in the Past
nmsnt.substack.com
October 31, 2026 at 7:35 PM
Philosophy of Natural Therapeutics 2
nmsnt.substack.com/p/philosophy...
nmsnt.substack.com/p/philosophy...
Atrium Therapeutics Unveils Promising Data on ATR 1072 for Treating PRKAG2 Syndrome#USA#Chicago#Atrium_Therapeutics#PRKAG2_Syndrome#ATR_1072
Atrium Therapeutics Unveils Promising Data on ATR 1072 for Treating PRKAG2 Syndrome
Atrium Therapeutics has announced new findings on ATR 1072 that may offer hope for patients with PRKAG2 syndrome, demonstrating reversal of disease features.
third-news.com
November 2, 2026 at 11:47 AM
Atrium Therapeutics Unveils Promising Data on ATR 1072 for Treating PRKAG2 Syndrome#USA#Chicago#Atrium_Therapeutics#PRKAG2_Syndrome#ATR_1072
Unfortunately, I have already started to hope again and am beyond the reach of gramineae-based therapeutics.
November 3, 2026 at 6:24 PM
Unfortunately, I have already started to hope again and am beyond the reach of gramineae-based therapeutics.
Bambusa Therapeutics, Inc. priced its IPO
Bambusa Therapeutics, Inc. has priced its IPO at $16.00 per share. The biotech firm is set to debut on October 30, 2026, underwritten by notable firms.
Biotech
#IPO #Biotech #BiologicalProductsNoDiagnostic #UnitedStates #IPONews
Bambusa Therapeutics, Inc. has priced its IPO at $16.00 per share. The biotech firm is set to debut on October 30, 2026, underwritten by notable firms.
Biotech
#IPO #Biotech #BiologicalProductsNoDiagnostic #UnitedStates #IPONews
Bambusa Therapeutics, Inc.
Bambusa Therapeutics, Inc. priced its IPO
www.discoveripo.com
October 30, 2026 at 9:02 PM
Bambusa Therapeutics, Inc. priced its IPO
Bambusa Therapeutics, Inc. has priced its IPO at $16.00 per share. The biotech firm is set to debut on October 30, 2026, underwritten by notable firms.
Biotech
#IPO #Biotech #BiologicalProductsNoDiagnostic #UnitedStates #IPONews
Bambusa Therapeutics, Inc. has priced its IPO at $16.00 per share. The biotech firm is set to debut on October 30, 2026, underwritten by notable firms.
Biotech
#IPO #Biotech #BiologicalProductsNoDiagnostic #UnitedStates #IPONews
📖 BJHM | Volume 87, Issue 10 (2026) — Now Live
📰Explore the latest research and insights in hospital medicine and clinical therapeutics.
🔗 Read the new issue: www.imrpress.com/journal/BJHM...
#HospitalMedicine #InternalMedicine #ClinicalTherapeutics #medicine #medsky #academicsky
📰Explore the latest research and insights in hospital medicine and clinical therapeutics.
🔗 Read the new issue: www.imrpress.com/journal/BJHM...
#HospitalMedicine #InternalMedicine #ClinicalTherapeutics #medicine #medsky #academicsky
November 3, 2026 at 6:56 AM
📖 BJHM | Volume 87, Issue 10 (2026) — Now Live
📰Explore the latest research and insights in hospital medicine and clinical therapeutics.
🔗 Read the new issue: www.imrpress.com/journal/BJHM...
#HospitalMedicine #InternalMedicine #ClinicalTherapeutics #medicine #medsky #academicsky
📰Explore the latest research and insights in hospital medicine and clinical therapeutics.
🔗 Read the new issue: www.imrpress.com/journal/BJHM...
#HospitalMedicine #InternalMedicine #ClinicalTherapeutics #medicine #medsky #academicsky
Ractigen Therapeutics Launches Phase II Clinical Trial of RAG-01 for Non-Muscle Invasive Bladder Cancer#China#Shanghai#Ractigen_Therapeutics#Bladder_Cancer#RAG-01
Ractigen Therapeutics Launches Phase II Clinical Trial of RAG-01 for Non-Muscle Invasive Bladder Cancer
Ractigen Therapeutics has initiated a Phase II clinical trial for its saRNA-based therapy RAG-01, targeting Non-Muscle Invasive Bladder Cancer. This innovative approach may address significant unmet needs in treatment.
third-news.com
November 2, 2026 at 2:05 PM
Ractigen Therapeutics Launches Phase II Clinical Trial of RAG-01 for Non-Muscle Invasive Bladder Cancer#China#Shanghai#Ractigen_Therapeutics#Bladder_Cancer#RAG-01
Could a single gene-editing therapy target a broad range of rare diseases? 2025–26 NEJM Editorial Fellow Katerina Lin, MD, explains the clinical implications of editing tRNA genes to broaden nonsense therapeutics. Go deeper on this subject: https://nej.md/4ttIiXg
November 1, 2026 at 2:01 PM
Could a single gene-editing therapy target a broad range of rare diseases? 2025–26 NEJM Editorial Fellow Katerina Lin, MD, explains the clinical implications of editing tRNA genes to broaden nonsense therapeutics. Go deeper on this subject: https://nej.md/4ttIiXg
💊 How can collaboration accelerate new treatments?
🧬🤝 @liverpooluni.bsky.social’s Therapeutics Innovation Frontier brings researchers, industry and health partners together to support the development of new therapeutic innovations.
👉
www.timeshighereducation.com/content/fost...
🧬🤝 @liverpooluni.bsky.social’s Therapeutics Innovation Frontier brings researchers, industry and health partners together to support the development of new therapeutic innovations.
👉
www.timeshighereducation.com/content/fost...
November 3, 2026 at 9:40 AM
💊 How can collaboration accelerate new treatments?
🧬🤝 @liverpooluni.bsky.social’s Therapeutics Innovation Frontier brings researchers, industry and health partners together to support the development of new therapeutic innovations.
👉
www.timeshighereducation.com/content/fost...
🧬🤝 @liverpooluni.bsky.social’s Therapeutics Innovation Frontier brings researchers, industry and health partners together to support the development of new therapeutic innovations.
👉
www.timeshighereducation.com/content/fost...
Azora Therapeutics – 13G holder update
• Holder: Coastlands Capital
• Stake: now 4.99%
• Note: counts convertible securities
• Filed: Nov 2 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
• Holder: Coastlands Capital
• Stake: now 4.99%
• Note: counts convertible securities
• Filed: Nov 2 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
Coastlands Capital LP: 4.99% of Azora Therapeutics
Schedule 13G/A filed Nov 2. Who filed, the stake, and how it changed.
elixstocks.com
November 3, 2026 at 1:43 AM
Azora Therapeutics – 13G holder update
• Holder: Coastlands Capital
• Stake: now 4.99%
• Note: counts convertible securities
• Filed: Nov 2 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
• Holder: Coastlands Capital
• Stake: now 4.99%
• Note: counts convertible securities
• Filed: Nov 2 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
CSTONE AND KIMIA THERAPEUTICS HAVE ENTERED A CLINICAL DEVELOPMENT COLLABORATION TO ADVANCE A NOVEL DRUG CANDIDATE TARGETING REPAIR PATHWAYS CRITICAL FOR SOLID TUMOR SURVIVAL
November 4, 2026 at 12:17 AM
CSTONE AND KIMIA THERAPEUTICS HAVE ENTERED A CLINICAL DEVELOPMENT COLLABORATION TO ADVANCE A NOVEL DRUG CANDIDATE TARGETING REPAIR PATHWAYS CRITICAL FOR SOLID TUMOR SURVIVAL
Dermata Therapeutics ($DRMA) – New 8.36% holder
• Holder: Bigger Capital Fund
• Stake: 0 → 8.36% (about $297K)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
• Holder: Bigger Capital Fund
• Stake: 0 → 8.36% (about $297K)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
Bigger Capital Fund LP: 8.36% of Dermata Therapeutics ($DRMA)
Schedule 13G filed Nov 2. Who filed, the stake, and how it changed.
elixstocks.com
November 2, 2026 at 9:33 PM
Dermata Therapeutics ($DRMA) – New 8.36% holder
• Holder: Bigger Capital Fund
• Stake: 0 → 8.36% (about $297K)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
• Holder: Bigger Capital Fund
• Stake: 0 → 8.36% (about $297K)
• About 13G: a passive investor, not seeking to influence the company
📊 More at www.elixstocks.com
Educational only. Not investment advice.
#Investing #Stocks
🚨 JUST IN
THC Therapeutics terminates ST Holdings share exchange deal, citing accounting difficulty
#SEC #stocks #investing #Mergers
🔗 secwatch.observer
THC Therapeutics terminates ST Holdings share exchange deal, citing accounting difficulty
#SEC #stocks #investing #Mergers
🔗 secwatch.observer
October 30, 2026 at 10:24 PM
🚨 JUST IN
THC Therapeutics terminates ST Holdings share exchange deal, citing accounting difficulty
#SEC #stocks #investing #Mergers
🔗 secwatch.observer
THC Therapeutics terminates ST Holdings share exchange deal, citing accounting difficulty
#SEC #stocks #investing #Mergers
🔗 secwatch.observer
Serina Therapeutics ($SER) – 13G holder update
• Holder: Sio Capital Management
• Stake: now 7.87% (about $4M)
• Filed: Nov 3 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
• Holder: Sio Capital Management
• Stake: now 7.87% (about $4M)
• Filed: Nov 3 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
Sio Capital Management, LLC: 7.87% of Serina Therapeutics ($SER)
Schedule 13G/A filed Nov 3. Who filed, the stake, and how it changed.
elixstocks.com
November 3, 2026 at 8:46 PM
Serina Therapeutics ($SER) – 13G holder update
• Holder: Sio Capital Management
• Stake: now 7.87% (about $4M)
• Filed: Nov 3 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
• Holder: Sio Capital Management
• Stake: now 7.87% (about $4M)
• Filed: Nov 3 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks #13G #ElixStocks
Ernexa Therapeutics ($ERNA) – 13G holder update
• Holder: Freebird Partners
• Stake: now 7% (about $231K)
• Note: counts convertible securities
• Filed: Oct 30 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks
• Holder: Freebird Partners
• Stake: now 7% (about $231K)
• Note: counts convertible securities
• Filed: Oct 30 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks
Freebird Partners LP: 7% of Ernexa Therapeutics ($ERNA)
Schedule 13G/A filed Oct 30. Who filed, the stake, and how it changed.
elixstocks.com
November 1, 2026 at 12:00 AM
Ernexa Therapeutics ($ERNA) – 13G holder update
• Holder: Freebird Partners
• Stake: now 7% (about $231K)
• Note: counts convertible securities
• Filed: Oct 30 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks
• Holder: Freebird Partners
• Stake: now 7% (about $231K)
• Note: counts convertible securities
• Filed: Oct 30 · Schedule 13G/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#Investing #Stocks
LENZ Therapeutics ($LENZ) – 13D holder update
• Holder: RA Capital Management
• Stake: now 0.2% (about $215K)
• Filed: Nov 2 · Schedule 13D/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#ActivistInvesting #Stocks #Investing #ElixStocks
• Holder: RA Capital Management
• Stake: now 0.2% (about $215K)
• Filed: Nov 2 · Schedule 13D/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#ActivistInvesting #Stocks #Investing #ElixStocks
RA Capital Management, LP: 0.2% of LENZ Therapeutics ($LENZ)
Schedule 13D/A filed Nov 2. Who filed, the stake, and how it changed.
elixstocks.com
November 2, 2026 at 10:47 PM
LENZ Therapeutics ($LENZ) – 13D holder update
• Holder: RA Capital Management
• Stake: now 0.2% (about $215K)
• Filed: Nov 2 · Schedule 13D/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#ActivistInvesting #Stocks #Investing #ElixStocks
• Holder: RA Capital Management
• Stake: now 0.2% (about $215K)
• Filed: Nov 2 · Schedule 13D/A
📊 Track ownership filings at www.elixstocks.com
Educational purposes only. Not investment advice.
#ActivistInvesting #Stocks #Investing #ElixStocks
Viking Therapeutics Set to Showcase Innovations at Major Healthcare Conferences#USA#San_Diego#Viking_Therapeutics#VKTX#metabolic_disorders
Viking Therapeutics Set to Showcase Innovations at Major Healthcare Conferences
Viking Therapeutics announces participation in upcoming investor conferences, showcasing its cutting-edge biopharmaceutical innovations for metabolic disorders.
third-news.com
November 3, 2026 at 10:00 PM
Viking Therapeutics Set to Showcase Innovations at Major Healthcare Conferences#USA#San_Diego#Viking_Therapeutics#VKTX#metabolic_disorders
Shield Therapeutics scraps profit forecast as US costs rise
Shield Therapeutics scraps profit forecast as US costs rise
Shield Therapeutics on Tuesday told investors it now expects to report a single-digit US dollar million loss for the full year to 31 December, abandoning…
dlvr.it
November 3, 2026 at 9:36 AM
Shield Therapeutics scraps profit forecast as US costs rise
#ADCT ADC Therapeutics Announces New Employee Inducement Grant
https://www.stocktitan.net/news/ADCT/adc-therapeutics-announces-new-employee-inducement-rya4cwl8owiq.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ADCT/adc-therapeutics-announces-new-employee-inducement-rya4cwl8owiq.html?utm_source=stocktitan-bluesky&utm_medium=social
www.stocktitan.net
November 2, 2026 at 9:05 PM
#ADCT ADC Therapeutics Announces New Employee Inducement Grant
https://www.stocktitan.net/news/ADCT/adc-therapeutics-announces-new-employee-inducement-rya4cwl8owiq.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ADCT/adc-therapeutics-announces-new-employee-inducement-rya4cwl8owiq.html?utm_source=stocktitan-bluesky&utm_medium=social
Variational AI partners with Merck on drug design 🤝
Variational AI and Merck team up to use Variational AI's Enki™ platform for designing small molecule therapeutics, with a potential deal value up to $349 million.
Variational AI and Merck team up to use Variational AI's Enki™ platform for designing small molecule therapeutics, with a potential deal value up to $349 million.
November 3, 2026 at 7:00 AM
Variational AI partners with Merck on drug design 🤝
Variational AI and Merck team up to use Variational AI's Enki™ platform for designing small molecule therapeutics, with a potential deal value up to $349 million.
Variational AI and Merck team up to use Variational AI's Enki™ platform for designing small molecule therapeutics, with a potential deal value up to $349 million.
Armed Cell Therapeutics Acquires Preclinical CAR-T Portfolio from Lakefront
Armed Cell Therapeutics Acquires Preclinical CAR-T Portfolio from Lakefront
On October 14, 2026, Armed Cell Therapeutics BV (“Armed Cell”) announced that it acquired a portfolio of preclinical CAR-T assets from Lakefront...
www.jdsupra.com
November 2, 2026 at 6:20 PM
Armed Cell Therapeutics Acquires Preclinical CAR-T Portfolio from Lakefront
LogicBio Therapeutics (LOGC) Expected to Post Quarterly Earnings on Tuesday
LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) is expected to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect LogicBio Therapeutics to post…
LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) is expected to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect LogicBio Therapeutics to post…
LogicBio Therapeutics (LOGC) Expected to Post Quarterly Earnings on Tuesday
LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) is expected to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect LogicBio Therapeutics to post…
news-area.com
November 1, 2026 at 7:59 PM
LogicBio Therapeutics (LOGC) Expected to Post Quarterly Earnings on Tuesday
LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) is expected to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect LogicBio Therapeutics to post…
LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) is expected to issue its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect LogicBio Therapeutics to post…
Antiviral Therapeutics Market Insights | Size & Outlook 2035 | WiseGuyReports www.wiseguyreports.com/reports/anti...
Antiviral Therapeutics Market Insights | Size & Outlook 2035
Antiviral Therapeutics Market Is Projected To Reach a Valuation of USD 63.9 Billion by 2035, Growing at a CAGR of 4.7% During the Forecast Period 2026 - 2035
www.wiseguyreports.com
November 3, 2026 at 11:38 AM
Antiviral Therapeutics Market Insights | Size & Outlook 2035 | WiseGuyReports www.wiseguyreports.com/reports/anti...
ADC Therapeutics Set for Upcoming Investor Conferences in November 2026#Switzerland#ADC_Therapeutics#ZYNLONTA#Lausanne#Ameet_Mallik
ADC Therapeutics Set for Upcoming Investor Conferences in November 2026
In November 2026, ADC Therapeutics will showcase its innovations in antibody drug conjugates at key investor conferences in Boston and London.
third-news.com
November 3, 2026 at 12:36 PM
ADC Therapeutics Set for Upcoming Investor Conferences in November 2026#Switzerland#ADC_Therapeutics#ZYNLONTA#Lausanne#Ameet_Mallik